IL-23 plays a critical role in EAE induced by the active immunization of C57BL/6 mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein ). It was initially assumed that the pathogenic effects of IL-23 were directly related to the generation, expansion and/or stabilization of autoreactive CD4 effector T cells could be categorized into functionally distinct Th subsets based on the production of polarized panels of effector cytokines [1] . Shortly thereafter, the Th1 subset was implicated in the pathogenesis of organ-specific autoimmunity. It was proposed that CNS tissue injury in EAE and MS was initiated by IL-12p70-stimulated, IFN-g-producing myelin-specific T cells [2, 3] . This hypothesis was reinforced by the observations that C57BL/6 mice deficient in IL-12p40 (one of the two component chains of IL-12p70) or IL-12 receptor b1 chain (IL-12Rb1, required for IL-12p70 signaling) were resistant to induction of EAE by active immunization against an immunodominant peptide of myelin oligodendrocyte glycoprotein ) [4, 5] . In contrast, subsequent studies in EAE were inconsistent with a Th1-based mechanism of autoimmune pathogenesis. Hence, C57BL/6 mice deficient in the IL-12p35 or IL-12Rb2 chains (the unique components of IL-12p70 and the IL-12 receptor, respectively), as well as mice deficient in the effector cytokine, IFN-g, remained susceptible to MOG 35-55 -induced disease [4, [6] [7] [8] [9] [10] . In fact, each of those genetically deficient mice experienced a more severe clinical course than their WT counterparts.
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In contrast, subsequent studies in EAE were inconsistent with a Th1-based mechanism of autoimmune pathogenesis. Hence, C57BL/6 mice deficient in the IL-12p35 or IL-12Rb2 chains (the unique components of IL-12p70 and the IL-12 receptor, respectively), as well as mice deficient in the effector cytokine, IFN-g, remained susceptible to MOG 35-55 -induced disease [4, [6] [7] [8] [9] [10] . In fact, each of those genetically deficient mice experienced a more severe clinical course than their WT counterparts.
The discovery of IL-23 in 2000 appeared to reconcile these paradoxes [11] . IL-23 is a heterodimeric cytokine produced by activated myeloid cells. It is composed of the common IL-12p40 chain (shared with IL-12p70) and a unique chain, termed IL-23p19. Its receptor, expressed on activated CD4
1 T cells and NK cells, is a heterodimer of IL-12Rb1 (shared with IL-12 receptor) complexed to IL-23R (a unique subunit). Numerous studies published between 2005 and the present have demonstrated that genetic deficiency or in vivo neutralization of the IL-23p19 chain confers resistance against EAE [12] [13] [14] [15] . Furthermore, several groups found that reactivation of myelin-reactive T cells in the presence of recombinant IL-23 enhances their pathogenicity [16, 17] . Based on these lines of evidence, it was concluded that IL-23, rather than IL-12p70, is critical for the manifestation of EAE, at least in MOG 35-55 -immunized C57BL/6 mice.
Commentary
The mechanism underlying the disease promoting effects of IL-23 proved to be elusive. IL-23-deficient mice are compromised in the generation of IL-17A-producing CD4 While there remains much to learn, the finding by Gyülvészi et al. that IL-23 influences CNS homing of myelin-reactive T cells and/or their survival/expansion in the CNS microenvironment [22] represents a significant advance in our understanding of the factors that control autoimmune demyelinating disease. Future investigations will likely lead to the discovery of new biomarkers and therapeutic targets based on trafficking molecules that are more specific to the interface between autoimmune effector cells and the blood-brain barrier.
